Jodie Tucker
Physician Assistant · Springfield, MONPI 1972555712
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.8% of the total across 421 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 24 manufacturers reported payments, led by AstraZeneca at 29.2% of the total. 2025 is the largest year on record at $2,413, 2.2 times the $1,109 reported in 2022. Among physician assistant clinicians in MO with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 421 payments — averaging $18.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$2K
- CSL Behring$2K
- Sanofi$555
- GSK$430
- Amgen$371
- Optinose US, Inc.$357
- plus $2K from 18 others
What the payments were for
- Food & beverage$7,67099%
- Education$921%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 117 | $2,267 |
| CSL Behring | 71 | $1,506 |
| Sanofi | 32 | $555 |
| GSK | 28 | $430 |
| Amgen(2 entities) | 22 | $371 |
| Optinose US, Inc. | 26 | $357 |
| Novartis | 18 | $332 |
| Regeneron Healthcare Solutions, Inc. | 14 | $329 |
| Grifols USA, LLC | 15 | $317 |
| Pfizer | 20 | $281 |
| Takeda Pharmaceuticals U.S.A., Inc. | 14 | $278 |
| Pharming Healthcare, Inc. | 15 | $236 |
| Genentech USA, Inc. | 6 | $101 |
| Boehringer Ingelheim | 4 | $70 |
| ARS Pharmaceuticals Operations, Inc. | 4 | $69 |
| Incyte Corporation | 3 | $53 |
| Blueprint Medicines Corporation | 3 | $53 |
| Octapharma USA, Inc. | 2 | $40 |
| Hikma Pharmaceuticals USA | 2 | $30 |
| Biocryst US Sales Co., LLC | 1 | $22 |
| Lilly USA, LLC | 1 | $18 |
| Teva Pharmaceuticals USA, Inc. | 1 | $18 |
| Merck | 1 | $15 |
| LEO Pharma Inc. | 1 | $15 |
How this compares
$7,762 in reported general payments places this provider in the 95th percentile of 1,380 physician assistant providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 25 | $16,465 |
| Spiriva RespimatTiotropium Bromide | 26 | $16,280 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 25 | $15,967 |
| Breo ElliptaFluticasone/Vilanterol | 21 | $9,170 |
| Advair HfaFluticasone Propion/Salmeterol | 20 | $8,842 |
| Epinephrine | 35 | $5,758 |
| Azelastine Hcl | 108 | $2,501 |
| Fluticasone Propionate | 94 | $1,132 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 20 | $934 |
| Montelukast Sodium | 67 | $457 |
| Famotidine | 39 | $416 |
| Ipratropium Bromide | 17 | $245 |
| Levocetirizine Dihydrochloride | 15 | $163 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta | $430 | $25,63546 claims |
| Boehringer IngelheimSpiriva Respimat | $70 | $16,28026 claims |
| AstraZenecaBreztri Aerosphere | $2,267 | $15,96725 claims |
| Hikma Pharmaceuticals USAEpinephrine | $30 | $5,75835 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,380 physician assistant providers in Missouri.
Other physician assistant in Springfield
- Marc ReitznerSpringfield$24K
- Morgan KuhnSpringfield$16K
- Michael PlastowSpringfield$11K
- James RivesSpringfield$8K
- Lauren CoppSpringfield$8K
- Amanda GoddardSpringfield$7K
- Jennifer DavissonKansas City$343K
- Andrew BergLees Summit$245K
- Sileen DowisKansas City$117K
- Daniel BeckSikeston$114K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.